CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
Li, LeiNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationLi, Chong, Shengwu Liu, Ruping Yan, Ning Han, Kwok-Kin Wong, and Lei Li. 2017. “CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer.” Theranostics 7 (1): 67-80. doi:10.7150/thno.16752. http://dx.doi.org/10.7150/thno.16752.
AbstractCancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology. Here, we implemented a novel chemoresistant prostate cancer patient-derived xenograft (PDX) model in NOD/SCID mice and identified CD54 as a candidate gene among the most highly enriched gene expression profiles in prostate tumors exposed to chronic cisplatin administration. Additional in vitro and in vivo assays showed that CD54 played a critical role in the self-renewal and tumorigenesis of prostate CSCs. Moreover, silencing CD54 greatly reduced the tumorigenesis of prostate cancers both in vitro and in vivo and significantly extended the survival time of tumor-bearing mice in a prostate cancer xenograft model. Dissection of the molecular mechanism revealed that the p38-Notch1 axis was the main downstream signaling pathway in CD54-mediated regulation of CSCs in prostate cancers. Together, these results established that CD54 could be a novel reliable prostate CSC marker and provided a new potential therapeutic target in prostate cancer via CD54-Notch1 signaling.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:30370923
- HMS Scholarly Articles